Sun Yifan, Long Haihua, Sun Lin, Sun Xiujuan, Pang Liping, Chen Jianlin, Yi Qingqun, Liang Tianwei, Shen Yongqi
Department of Clinical Laboratory, Liuzhou Municipal Liutie Central Hospital, Liuzhou, Guangxi China.
Department of Endoscopy, Liuzhou Municipal Liutie Central Hospital, Liuzhou, Guangxi China.
Cancer Cell Int. 2019 Oct 1;19:253. doi: 10.1186/s12935-019-0967-y. eCollection 2019.
Phosphoglucomutase (PGM), a key enzyme in the metabolism of glucose-1-phosphate and glucose-6-phosphate, has been found to be associated with proliferation, invasion, and metastasis of cancer. However, the expression and function of PGM5 in colorectal cancer (CRC) remains unknown.
We tested PGM5 mRNA and protein expression levels in 79 CRC tissue and their matched adjacent tissue samples by qRT-PCR and immunohistochemistry, respectively. Overall survival (OS) was estimated with the Kaplan-Meier method and compared between groups with the log-rank test. We performed multivariable Cox regression analyses to identify factors associated with CRC risk. The cell proliferation, migration and invasion abilities of CRC cells were detected by using CCK-8, Transwell migration and invasion assays, respectively.
The PGM5 protein levels expression in CRC tissues were significantly lower than those in the adjacent tissues (t = 5.035, < 0.001), and Kaplan-Meier analysis indicated that low PGM5 expression were significantly associated with poor overall survival (= 0.0069). Univariate and multivariate analyses demonstrated that PGM5 was an independent risk factor for overall survival (hazard ratio = 0.3951, = 0.014). PGM5 overexpression significantly inhibited the proliferation, invasion and migration abilities of CRC cells. On the contrary, knockdown of PGM5 promotes the invasion and migration of CRC cells.
PMG5 regulates proliferation, invasion, and migration in the CRC and decreased PGM5 is associated with poor prognosis. Therefore, PGM5 is a promising biomarker in CRC and decreased PGM5 may predict poor overall survival in patients with CRC.
磷酸葡萄糖变位酶（PGM）是1-磷酸葡萄糖和6-磷酸葡萄糖代谢中的关键酶，已发现其与癌症的增殖、侵袭和转移有关。然而，PGM5在结直肠癌（CRC）中的表达和功能仍不清楚。
我们分别通过qRT-PCR和免疫组织化学检测了79例CRC组织及其配对的相邻组织样本中PGM5 mRNA和蛋白表达水平。采用Kaplan-Meier法估计总生存期（OS），并通过对数秩检验进行组间比较。我们进行了多变量Cox回归分析以确定与CRC风险相关的因素。分别使用CCK-8、Transwell迁移和侵袭实验检测CRC细胞的增殖、迁移和侵袭能力。
CRC组织中PGM5蛋白水平表达明显低于相邻组织（t = 5.035，P < 0.001），Kaplan-Meier分析表明低PGM5表达与较差的总生存期显著相关（P = 0.0069）。单因素和多因素分析表明PGM5是总生存期的独立危险因素（风险比 = 0.3951，P = 0.014）。PGM5过表达显著抑制CRC细胞的增殖、侵袭和迁移能力。相反，敲低PGM5可促进CRC细胞的侵袭和迁移。
PMG5调节CRC的增殖、侵袭和迁移，PGM5降低与预后不良相关。因此，PGM5是CRC中有前景的生物标志物，PGM5降低可能预测CRC患者的总生存期较差。
